Online first
Research Paper
Published online: 2024-06-07

open access

Page views 139
Article views/downloads 79
Get Citation

Connect on Social Media

Connect on Social Media

Validation of Polish version of Gastrointestinal Dysfunction Scale for Parkinson’s Disease

Julia M. Nowak1, Aleksandra Antoniak1, Mateusz Kopczyński1, Weronika Zając1, Karol Sadowski1, Łukasz Milanowski2, Dariusz Koziorowski2, Monika Figura2

Abstract

Aim of study. The Gastrointestinal Dysfunction Scale for Parkinson’s Disease (GIDS-PD) is a novel, disease-specific self-report questionnaire used to quantitatively assess features of gastrointestinal dysfunction symptoms in patients with Parkinson’s Disease. The aim of this paper was to validate the Polish translation of the scale, to summarise its consistency with the English language version, and to assess its clinimetric properties.

Clinical rationale for study. Gastrointestinal dysfunction is a common and often debilitating manifestation of Parkinson’s Disease (PD). Gastrointestinal symptoms are also considered to be prodromal features of this disease. To date, there has been no scale in Polish that has precisely assessed gastrointestinal symptoms in patients with PD.

Material and methods. The GIDS-PD was translated into Polish by two investigators (M.K. and J.N.). A back-translation was completed by two separate investigators (M.F. and A.A.) who were not involved in the original translation. Afterwards, 10 Polish PD patients underwent cognitive pre-testing. After the final translation was officially approved by the Movement Disorder Society, it was tested on 64 individuals with PD during field testing. For the purpose of testing scale reliability, 20 of the patients recruited for field testing underwent the GIDS-PD for a second time after 8-12 weeks.

Results. The GIDS-PD demonstrated overall good consistency (Cronbach’s alpha of 0.74, ICC of 0.74). Regarding the individual domains, the constipation subscore demonstrated good reliability, the bowel irritability subscore demonstrated moderate reliability, and the upper GI subscore demonstrated poor reliability. Upper GI symptoms seem to be less pronounced, and also more varied, in the Polish PD population than in its English language counterpart.

Conclusions and clinical implications. This paper provides a validated Polish translation of the GIDS-PD questionnaire. We highly recommend using the GIDS-PD for research purposes, as well as everyday clinical practice in the Polish PD population.

Article available in PDF format

View PDF Download PDF file

References

  1. GBD 2016 Parkinson's Disease Collaborators, GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018; 17(11): 939–953.
  2. Willis AW, Roberts E, Beck JC, et al. Parkinson’s Foundation P4 Group, Parkinson’s Foundation P4 Group, Parkinson’s Foundation P4 Group, Parkinson’s Foundation P4 Group. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 2018; 4(1): 21.
  3. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003; 157(11): 1015–1022.
  4. Balestrino R, Schapira AHV, Balestrino R, et al. Parkinson disease. Eur J Neurol. 2020; 27(1): 27–42.
  5. Rahman S, Griffin HJ, Quinn NP, et al. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord. 2008; 23(10): 1428–1434.
  6. Siuda J. Importance of non-motor symptoms in PD and atypical parkinsonism. Neurol Neurochir Pol. 2021; 55(6): 503–507.
  7. Schapira AHV, Chaudhuri KR, Jenner P, et al. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017; 18(7): 435–450.
  8. Kwaśniak-Butowska M, Dulski J, Pierzchlińska A, et al. Cardiovascular dysautonomia and cognition in Parkinson's Disease - a possible relationship. Neurol Neurochir Pol. 2021; 55(6): 525–535.
  9. Figura M, Friedman A. In search of Parkinson's disease biomarkers - is the answer in our mouths? A systematic review of the literature on salivary biomarkers of Parkinson's disease. Neurol Neurochir Pol. 2020; 54(1): 14–20.
  10. Cholewa J, Boczarska-Jedynak M, Opala G. Influence of physiotherapy on severity of motor symptoms and quality of life in patients with Parkinson disease. Neurol Neurochir Pol. 2013; 47(3): 256–262.
  11. Malkiewicz JJ, Kasprzyk AG, Waksmundzki D, et al. Risk factors for dementia in Parkinson's Disease - the overuse of anticholinergic drugs. Neurol Neurochir Pol. 2023; 57(5): 405–413.
  12. Stocchi F, Torti M. Constipation in Parkinson's Disease. Int Rev Neurobiol. 2017; 134: 811–826.
  13. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease. Neurobiol Dis. 2012; 46(3): 559–564.
  14. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24(2): 197–211.
  15. Horsager J, Knudsen K, Sommerauer M. Clinical and imaging evidence of brain-first and body-first Parkinson's disease. Neurobiol Dis. 2022; 164: 105626.
  16. Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022; 22(11): 657–673.
  17. Nowak JM, Kopczyński M, Friedman A, et al. Microbiota Dysbiosis in Parkinson Disease-In Search of a Biomarker. Biomedicines. 2022; 10(9): 2057.
  18. Murros KE, Huynh VyA, Takala TM, et al. Bacteria Are Associated With Parkinson's Disease. Front Cell Infect Microbiol. 2021; 3(11): 652617.
  19. Camacho M, Greenland JC, Williams-Gray CH, et al. The Gastrointestinal Dysfunction Scale for Parkinson's Disease. Mov Disord. 2021; 36(10): 2358–2366.
  20. Drennan J. Cognitive interviewing: verbal data in the design and pretesting of questionnaires. J Adv Nurs. 2003; 42(1): 57–63.
  21. Parent M. Handling Item-Level Missing Data. The Counseling Psychologist. 2012; 41(4): 568–600.
  22. Roth P, Switzer F, Switzer D. Missing Data in Multiple Item Scales: A Monte Carlo Analysis of Missing Data Techniques. Organizational Research Methods. 2016; 2(3): 211–232.
  23. George D, Mallery P. IBM SPSS Statistics 26 Step by Step. , New York 2019.
  24. Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2): 155–163.
  25. Field A. Discovering statistics using SPSS. 3rd ed. SAGE Publications, Los Angeles; London: Sage 2009.
  26. Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate Use and Interpretation. Anesth Analg. 2018; 126(5): 1763–1768.
  27. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995; 4(4): 293–307.
  28. Gastrointestinal Dysfunction Scale for Parkinson’s Disease (GIDS-PD), Japanese version. Movement Disorders Society- Clinical Outcome Assesments Movement Disorders Society; 2024. https://www.movementdisorders.org/MDS-Files1/PDFs/Rating-Scales/GIDS-PD_Japanese_Final.pdf (20.11.2023).
  29. Gong S, Gao Y, Liu J, et al. The prevalence and associated factors of dysphagia in Parkinson's disease: A systematic review and meta-analysis. Front Neurol. 2022; 6(13): 1000527.
  30. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl. 1999; 231: 3–8.
  31. Sung HY, Park JW, Kim JS. The frequency and severity of gastrointestinal symptoms in patients with early Parkinson's disease. J Mov Disord. 2014; 7(1): 7–12.
  32. Yu QJ, Yu SY, Zuo LJ, et al. Parkinson disease with constipation: clinical features and relevant factors. Sci Rep. 2018; 8(1): 567.
  33. Guo X, Song W, Chen Ke, et al. Disease duration-related differences in non-motor symptoms: a study of 616 Chinese Parkinson's disease patients. J Neurol Sci. 2013; 330(1-2): 32–37.
  34. Lubomski M, Davis RL, Sue CM. Gastrointestinal dysfunction in Parkinson's disease. J Neurol. 2020; 267(5): 1377–1388.
  35. Pan R, Wang L, Xu X, et al. Crosstalk between the Gut Microbiome and Colonic Motility in Chronic Constipation: Potential Mechanisms and Microbiota Modulation. Nutrients. 2022; 14(18): 3704.
  36. Nitkowska M, Czyżyk M, Friedman A. Reproductive life characteristics in females affected with Parkinson's disease and in healthy control subjects - a comparative study on Polish population. Neurol Neurochir Pol. 2014; 48(5): 322–327.
  37. Marras C, Saunders-Pullman R. The complexities of hormonal influences and risk of Parkinson's disease. Mov Disord. 2014; 29(7): 845–848.
  38. Zhao Z, Ning J, Bao XQ, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021; 9(1): 226.
  39. DuPont HL, Suescun J, Jiang ZD, et al. Fecal microbiota transplantation in Parkinson's disease-A randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 2023; 14: 1104759.
  40. Xue LJ, Yang XZ, Tong Q, et al. Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study. Medicine (Baltimore). 2020; 99(35): e22035.



Neurologia i Neurochirurgia Polska